Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Apr 7;35(6):1561–1573. doi: 10.3892/ijmm.2015.2173

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2015, Spandidos Publications

This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.

PMC Copyright notice

(A) Growth curves for U373MG tumor xenografts in vivo. From day 16 after treatment, compared to the vehicle control group and the control-siRNA group, the growth of U373MG cells in vivo was slower in the activating transcription factor 3 (ATF3)-siRNA group and tumor volume was significantly reduced (P<0.05). Growth in the cisplatin group was much slower, and tumor volume was much smaller (P<0.05) and tumor growth in the ATF3-siRNA + cisplatin group was the slowest, with the smallest volume (P<0.05). (B) Tumor size on day 21. (a) Vehicle control group, (b) control-siRNA group, (c) ATF3-siRNA group, (d) cisplatin group, (e) ATF3-siRNA + cisplatin group. Compared to the vehicle control group and the control-siRNA group, tumor volume was significantly reduced (P<0.05) in the ATF3-siRNA group. Tumor volume was much smaller (P<0.05) in the cisplatin group, and smallest in the ATF3-siRNA + cisplatin group (P<0.05).